Aldeyra director granted new stock options
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share. The grants cover 4,977, 5,309, and 70,000 underlying shares, respectively, and are reported as compensation-related acquisitions rather than market purchases.
According to the filing, each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided Bronstein continues serving on the Board of Directors and, for two grants, on the Nominating/Corporate Governance and Audit Committees through the applicable vesting dates. All options are scheduled to expire on June 8, 2036 if not exercised.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 70,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 5,309 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 4,977 | $0.00 | $0.00 |
Footnotes (3)
- F1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- F2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
- F3. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
expiration date financial
Nominating/Corporate Governance Committee financial
Audit Committee financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aldeyra Therapeutics (ALDX) director Ben Bronstein report in this Form 4?
Are Ben Bronstein’s Aldeyra (ALDX) option grants open-market purchases or compensation awards?
What are the vesting terms of Ben Bronstein’s new Aldeyra (ALDX) stock options?
What is the exercise price and expiration date of the Aldeyra (ALDX) options granted to Ben Bronstein?
AI-generated analysis. How Rhea-AI works. Not financial advice.